Balancing Glycolytic Flux: the Role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in Cancer Metabolism

Overview

Journal Cancer Metab

Publisher Biomed Central

Specialty Oncology

Date 2013 Nov 28

PMID 24280138

Citations 128

Authors

Susana Ros

Almut Schulze

Affiliations

Soon will be listed here.

Abstract

The increased glucose metabolism in cancer cells is required to fulfill their high energetic and biosynthetic demands. Changes in the metabolic activity of cancer cells are caused by the activation of oncogenes or loss of tumor suppressors. They can also be part of the metabolic adaptations to the conditions imposed by the tumor microenvironment, such as the hypoxia response. Among the metabolic enzymes that are modulated by these factors are the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases (PFKFBs), a family of bifunctional enzymes that control the levels of fructose 2,6-bisphosphate (Fru-2,6-P2). This metabolite is important for the dynamic regulation of glycolytic flux by allosterically activating the rate-limiting enzyme of glycolysis phosphofructokinase-1 (PFK-1). Therapeutic strategies designed to alter the levels of this metabolite are likely to interfere with the metabolic balance of cancer cells, and could lead to a reduction in cancer cell proliferation, invasiveness and survival. This article will review our current understanding of the role of PFKFB proteins in the control of cancer metabolism and discuss the emerging interest in these enzymes as potential targets for the development of antineoplastic agents.

Citing Articles

Metabolic reprogramming of glucose: the metabolic basis for the occurrence and development of hepatocellular carcinoma.

Wang K, Li X, Guo S, Chen J, Lv Y, Guo Z Front Oncol. 2025; 15:1545086.

PMID: 39980550 PMC: 11839411. DOI: 10.3389/fonc.2025.1545086.

neural stem progenitor cells exhibit a transient metabolic shift toward glycolysis during spinal cord regeneration.

Slater P, Dominguez-Romero M, Campos G, Aravena V, Cavieres-Lepe J, Eisner V Front Cell Dev Biol. 2025; 13:1529093.

PMID: 39944083 PMC: 11814455. DOI: 10.3389/fcell.2025.1529093.

Impact of glycolysis enzymes and metabolites in regulating DNA damage repair in tumorigenesis and therapy.

Sun F, Li W, Du R, Liu M, Cheng Y, Ma J Cell Commun Signal. 2025; 23(1):44.

PMID: 39849559 PMC: 11760674. DOI: 10.1186/s12964-025-02047-9.

Targeting aldolase A in hepatocellular carcinoma leads to imbalanced glycolysis and energy stress due to uncontrolled FBP accumulation.

Snaebjornsson M, Poeller P, Komkova D, Rohrig F, Schlicker L, Winkelkotte A Nat Metab. 2025; 7(2):348-366.

PMID: 39833612 PMC: 11860237. DOI: 10.1038/s42255-024-01201-w.

Metabolic Crossroad Between Macrophages and Cancer Cells: Overview of Hepatocellular Carcinoma.

Santarsiero A, Convertini P, Iacobazzi D, Infantino V, Todisco S Biomedicines. 2025; 12(12.

PMID: 39767591 PMC: 11727080. DOI: 10.3390/biomedicines12122684.

References

Wang C, Fisk B, Wadehra M, Su H, Braun J . Overexpression of murine fizzy-related (fzr) increases natural killer cell-mediated cell death and suppresses tumor growth. Blood. 2000; 96(1):259-63. View

Nathan C, Ding A . SnapShot: Reactive Oxygen Intermediates (ROI). Cell. 2010; 140(6):951-951.e2. DOI: 10.1016/j.cell.2010.03.008. View

Muniyappa H, Song S, Mathews C, Das K . Reactive oxygen species-independent oxidation of thioredoxin in hypoxia: inactivation of ribonucleotide reductase and redox-mediated checkpoint control. J Biol Chem. 2009; 284(25):17069-17081. PMC: 2719345. DOI: 10.1074/jbc.M109.008557. View

Minchenko O, Opentanova I, Minchenko D, Ogura T, Esumi H . Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation. FEBS Lett. 2004; 576(1-2):14-20. DOI: 10.1016/j.febslet.2004.08.053. View

Garcia-Higuera I, Manchado E, Dubus P, Canamero M, Mendez J, Moreno S . Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol. 2008; 10(7):802-11. DOI: 10.1038/ncb1742. View

Kim J, Dang C . Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006; 66(18):8927-30. DOI: 10.1158/0008-5472.CAN-06-1501. View

Darville M, Antoine I, Rousseau G . Characterization of an enhancer upstream from the muscle-type promoter of a gene encoding 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Nucleic Acids Res. 1992; 20(14):3575-83. PMC: 334004. DOI: 10.1093/nar/20.14.3575. View

Depre C, Rider M, Hue L . Mechanisms of control of heart glycolysis. Eur J Biochem. 1999; 258(2):277-90. DOI: 10.1046/j.1432-1327.1998.2580277.x. View

Frenzel J, Schellenberger W, Eschrich K, Hofmann E . Control of the fructose 6-phosphate/fructose 2,6-bisphosphate cycle by sn-glycerol 3-phosphate. Biomed Biochim Acta. 1988; 47(6):461-70. View

10.

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

11.

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

12.

Rider M, Van Damme J, Vertommen D, Michel A, Vandekerckhove J, Hue L . Evidence for new phosphorylation sites for protein kinase C and cyclic AMP-dependent protein kinase in bovine heart 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. FEBS Lett. 1992; 310(2):139-42. DOI: 10.1016/0014-5793(92)81315-d. View

13.

Kitamura K, Kangawa K, Matsuo H, Uyeda K . Phosphorylation of myocardial fructose-6-phosphate,2-kinase: fructose-2,6-bisphosphatase by cAMP-dependent protein kinase and protein kinase C. Activation by phosphorylation and amino acid sequences of the phosphorylation sites. J Biol Chem. 1988; 263(32):16796-801. View

14.

Dupriez V, Darville M, Antoine I, Gegonne A, Ghysdael J, Rousseau G . Characterization of a hepatoma mRNA transcribed from a third promoter of a 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-encoding gene and controlled by ets oncogene-related products. Proc Natl Acad Sci U S A. 1993; 90(17):8224-8. PMC: 47321. DOI: 10.1073/pnas.90.17.8224. View

15.

Minchenko D, Mykhalchenko V, Tsuchihara K, Kanehara S, Yavorovsky O, Zavgorodny I . Alternative splice variants of rat 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase-4 mRNA. Ukr Biokhim Zh (1999). 2009; 80(4):66-73. View

16.

Ros S, Santos C, Moco S, Baenke F, Kelly G, Howell M . Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov. 2012; 2(4):328-43. DOI: 10.1158/2159-8290.CD-11-0234. View

17.

Okar D, Lange A . Fructose-2,6-bisphosphate and control of carbohydrate metabolism in eukaryotes. Biofactors. 1999; 10(1):1-14. DOI: 10.1002/biof.5520100101. View

18.

Moon J, Jin W, Kwak J, Kim H, Yun M, Kim J . Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J. 2010; 433(1):225-33. DOI: 10.1042/BJ20101104. View

19.

Miralpeix M, Azcon-Bieto J, Bartrons R, Argiles J . The impairment of respiration by glycolysis in the Lewis lung carcinoma. Cancer Lett. 1990; 50(3):173-8. DOI: 10.1016/0304-3835(90)90261-u. View

20.

Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A . Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008; 7(1):110-20. DOI: 10.1158/1535-7163.MCT-07-0482. View